MEI PHARMA, INC.

Analyst Reco. MEI Pharma, Inc.

Equities

MEIP

US55279B3015

Delayed Nasdaq Other stock markets 10:38:28 2024-04-30 am EDT			5-day change	1st Jan Change
3.08 ^USD	0.00%		-7.57%	-46.90%

Apr. 11	MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data	CI
Apr. 11	MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Stifel Adjusts Price Target on MEI Pharma to $7 From $8, Keeps Hold Rating	Feb. 14	MT
Stifel Adjusts Price Target on MEI Pharma to $9 From $10, Maintains Hold Rating	23-09-27	MT
Stifel Adjusts MEI Pharma's Price Target to $10 From $0.50, Keeps Hold Rating	23-05-12	MT
Stifel Nicolaus Adjusts MEI Pharma Price Target to $0.50 From $2, Maintains Hold Rating	23-02-13	MT
HC Wainwright Adjusts Price Target on MEI Pharma to $2 From $5, Maintains Buy Rating	23-02-13	MT
Jefferies Downgrades MEI Pharma to Underperform From Hold, Adjusts Price Target to $0.10 From $0.40	23-02-08	MT
BTIG Downgrades MEI Pharma to Neutral From Buy	22-12-06	MT
Truist Securities Downgrades MEI Pharma to Hold From Buy	22-12-06	MT
Brookline Capital Markets Adjusts MEI Pharma Price Target to $15 From $20, Maintains Buy Rating	22-03-25	MT
BTIG Adjusts MEI Pharma's Price Target to $4 From $11, Reiterates Buy Rating	22-03-25	MT
Truist Securities Adjusts MEI Pharma's Price Target to $3 From $8, Reiterates Buy Rating	22-03-25	MT
Wells Fargo Downgrades MEI Pharma to Equalweight From Overweight, Adjusts Price Target to $2 From $13	22-03-25	MT
HC Wainwright Adjusts MEI Pharma's Price Target to $5 From $10, Reiterates Buy Rating	22-03-25	MT
Stifel Lowers MEI Pharma to Hold From Buy, Price Target to $2 From $6	22-03-25	MT
Jefferies Cuts MEI Pharma to Hold From Buy, Price Target to $1 From $4	22-03-25	MT
Jefferies Starts MEI Pharma at Buy With $4 Price Target	22-02-03	MT
MEI Pharma Says Treatment With Follicular Lymphoma Drug Candidate Shows Complete Response Rate of Over 35% in Mid-Stage Trial	21-11-30	MT
MEI Pharma Announces Pre-Specified Response Rate Exceeded in Dose-Escalation Study of Me-401 in Chronic Lymphocytic Leukemia and Follicular Lymphoma	17-05-31	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Like the pros, access all the transcripts and spot the best opportunities before anyone else.

Unlock them now!

fermer